-
肿瘤严重危及人类生命健康,而放射治疗是临床肿瘤治疗的重要手段之一。提高放射治疗中肿瘤细胞的敏感性是提高肿瘤放疗疗效的关键。因此,放射增敏药物的研究已成为肿瘤放射治疗学及放射生物学领域的热点问题之一。目前临床使用的放疗增敏药物主要包括细胞毒类药物、靶向药物以及中药制剂3大类。临床使用放疗增敏药物的主要目的是通过提高肿瘤细胞的辐射敏感性,达到提高电离辐射对肿瘤细胞的杀伤作用,降低辐射对正常组织的损伤,提高放疗疗效,减少不良反应。
肿瘤放射增敏药物的研究进展
The research progression of cancer radio-sensitization drugs
-
摘要: 放射治疗是临床肿瘤治疗的重要手段之一。肿瘤细胞的放射敏感性是影响肿瘤放疗疗效的关键因素。放射增敏药物能够增强机体的放射敏感性,通过提高肿瘤细胞的放射敏感性达到降低照射剂量、提高放疗疗效、降低正常组织损伤的目的。现有的放射增敏药物主要分为细胞毒类药物、靶向药物以及中药制剂3大类。该文将对肿瘤放射增敏药物的作用机制、现状及相关研究进展进行综述。Abstract: Radiation therapy occupies an irreplaceable position for cancer therapy. The sensibility of the tumor is a fundamental factor that influences the treatment effectiveness. The drug of radiosensitization can reinforce the radiosensitivity by raising the sensitivity of the tumors in order to decrease the expose dose and the lesion of normal tissue. At present there are cytotoxic drug, targeted drug and Chinese drugs pharmaceutics. This article reviews the mechanism of action, status quo and research progression of the radiosensitization drugs.
-
Key words:
- Neoplasms /
- Radiation therapy /
- Radiosensitization
-
[1] Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes[J]. Chem Biodivers, 2010, 7(3): 543-566. doi: 10.1002/cbdv.200800340 [2] Ren F, Chen R, Wang Y, et al. Paclitaxel-loaded poly(n-butylcyanoacrylate)nanoparticle delivery system to overcome multidrug resistance in ovarian cancer[J]. Pharm Res, 2011, 28(4): 897-906. doi: 10.1007/s11095-010-0346-9 [3] Cao W, Shiverick K, Namiki K, el al.Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bel-2 expressing prostate cancer cells to irradiation[J]. World J Urol, 2008, 26(5): 509-516. doi: 10.1007/s00345-008-0289-5 [4] Yoshida D, Ebara T, Sato Y, et al. Interaction of radiation and pemetrexed on a human malignant mesothlioma cell line in vitro[J]. Anticancer Res, 2011, 31(9): 2847-2851. [5] Morgan MA, Parsels LA, Maybaum J, et al. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review[J]. Clin Cancer Res, 2008, 14(21): 6744-6750. doi: 10.1158/1078-0432.CCR-08-1032 [6] Murphy JD, Lucas DR, Somnay YR, et al. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma[J]. Transl Oncol, 2008, 1(1): 50-56. doi: 10.1593/tlo.07121 [7] El Shafie RA, Habermehl D, Rieken S, et al. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines[J]. J Radiat Res, 2013, 54 Suppl 1: S1113-1119. [8] Yasui H, Ogura A, Asanuma T, et al. Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo[J]. Br J Cancer, 2008, 99(9): 1442-1452. doi: 10.1038/sj.bjc.6604720 [9] Illum H. Irinotecan and radiosensitization in rectal cancer[J]. Anticancer Drugs, 2011, 22(4): 324-329. doi: 10.1097/CAD.0b013e3283425c14 [10] Nam C, DoiK, Nakayaam H. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and all ATM/p53-related pathway[J]. Histol Histopathol, 2010, 25(4): 485-493. [11] Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck[J]. Health Technol Assess, 2009, 13 Suppl 1: S49-54. [12] Stagno F, Vigneri P, Del Fabro V, et al. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias[J]. Acta Oncol, 2010, 49(1): 109-110. [13] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28. doi: 10.1016/S1470-2045(09)70311-0 [14] Sato Y, Ebara T, Sunaga N, et al. Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro[J]. Anticancer Res, 2012, 32(11): 4877-4881. [15] Rao K, Kalapurakal S, Chalasani P, et al. A phase Ⅱ study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer[J]. Cancer Chemother Pharmacol, 2013, 72(3): 545-552. doi: 10.1007/s00280-013-2225-7 [16] Visentin M, Biason P, Toffoli G. Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents[J]. Pharmacol Ther, 2010, 128(1): 82-90. doi: 10.1016/j.pharmthera.2010.05.005 [17] 李英杰, 于长海, 张文, 等. COX-2与LRP在非小细胞肺癌中的表达与肺癌预后的关系[J].临床肺科杂志, 2010, 15(12): 1707-1709. doi: 10.3969/j.issn.1009-6663.2010.12.011
[18] Inoue T, Anai S, Onishi S, et al. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model[J]. BMC Urol, 2013, 13: 1. doi: 10.1186/1471-2490-13-1 [19] Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies[J]. Head Neck, 2008, 30(2): 262-266. doi: 10.1002/hed.20674 [20] Viswanathan AN, Lee H, Berkowitz R, et al. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer[J]. Gynecol Oncol, 2014, 132(1): 55-60. [21] Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy[J]. Br J Cancer, 2009, 100(5): 747-757. doi: 10.1038/sj.bjc.6604939 [22] Tamatani T, Takamaru N, Hara K, et al. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells[J]. Int J Oncol, 2013, 42(3): 935-944. doi: 10.3892/ijo.2013.1786 [23] Isebaert SF, Swinnen JV, McBride WH, et al. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1): 239-247. doi: 10.1016/j.ijrobp.2011.03.030 [24] 吴冬梅, 杨荣宁.莪术油对鼻咽癌CNE-2细胞的凋亡及放疗增敏机制的影响[J].肿瘤防治研究, 2008, 11(35): 778-782.
[25] 曹远东, 孙新臣, 成红艳, 等.汉防己甲素配合放射线增敏治疗鼻咽癌的临床研究[J].东南大学学报, 2008, 27(2): 106-109. doi: 10.3969/j.issn.1671-6264.2008.02.009
[26] 刘少龙, 罗辉, 谢淑华.三氧化二砷对胃癌细胞放射增敏作用的研究[J].江西医学院学报, 2009, 49(2): 47-50. doi: 10.3969/j.issn.1000-2294.2009.02.012
[27] 汤继英, 潘东风, 石小燕, 等.三氧化二砷对人宫颈癌细胞的放射增敏作用[J].郧阳医学院学报, 2008, 27(2): 109-111.
[28] 谢良喜, 李德锐, 林英城, 等.三氧化二砷对鼻咽癌离体细胞的放射增敏作用[J].中华放射医学与防护杂志, 2004, 24(3): 240-242. doi: 10.3760/cma.j.issn.0254-5098.2004.03.018
[29] 杨百霞, 杨曦, 朱琪伟, 等.盐酸小檗碱对乏氧食管癌细胞的放射增敏作用[J].中华放射医学与防护杂志, 2013, 33(5): 484-488. doi: 10.3760/cma.j.issn.0254-5098.2013.05.007
[30] 王振华, 师国珍, 张宁, 等.去甲斑蝥素对肺癌A549细胞株体外放射增敏作用[J].中国实用医刊, 2009, 36(24): 8-10. doi: 10.3760/cma.j.issn.1674-4756.2009.24.004
[31] 封阳, 周媛媛, 杨巍, 等.青蒿素联合60Co γ射线对HeIa和SiHa细胞所致DNA损伤的研究[J].苏州大学学报:医学版, 2011, 31(1): 2-5.
[32] 陈遐林, 曹建平, 纪蓉, 等.二氢青蒿素对人宫颈癌HeLa细胞放射增敏作用的研究[J].中华放射医学与防护杂志, 2009, 29(4): 360-363. doi: 10.3760/cma.j.issn.0254-5098.2009.04.003
[33] 郭素敏, 宗会迁, 孙超英, 等.中药扶正联合放射治疗肺癌的临床研究[J].河北医药, 2008, 30(8): 1164 -1165. doi: 10.3969/j.issn.1002-7386.2008.08.039
[34] 刘军叶, 郭鹞, 郭国祯. Bcl-2基因特异性小干涉RNA增强食管癌细胞辐射敏感性的实验研究[J].国际放射医学核医学杂志, 2006, 30(2): 110-113. doi: 10.3760/cma.j.issn.1673-4114.2006.02.014
计量
- 文章访问数: 3073
- HTML全文浏览量: 1761
- PDF下载量: 5